Clinical Context Prediabetes affects approximately 96 million American adults—more than one-third of the adult population—and represents a critical window for…
Browsing: PICO
Summary: In adults with obesity-related HFpEF (BMI ≥30) from pooled STEP-HFpEF trials (n=1,145), stratified by baseline diuretic use, once-weekly semaglutide…
A post-hoc pooled analysis of four semaglutide trials reports fewer worsening heart failure events in participants with HFpEF, with no significant effect on cardiovascular death. PICO summary and expert commentary.
A prespecified analysis of the FLOW randomised trial found once-weekly semaglutide reduced heart failure events and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. PICO summary and expert commentary.
A prespecified mortality analysis of the SELECT trial found that semaglutide 2.4 mg lowered all-cause death in adults with obesity and cardiovascular disease but no diabetes. PICO summary and expert commentary.
A secondary analysis of the pooled STEP-HFpEF and STEP-HFpEF DM trials shows semaglutide 2.4 mg improves symptoms, weight, and exercise capacity in obesity-related HFpEF consistently across baseline C-reactive protein strata. PICO summary and expert commentary.
Prespecified subgroup analysis of the pooled STEP-HFpEF Program testing whether atrial fibrillation modifies semaglutide’s effect on symptoms in obesity-related HFpEF. PICO summary and expert commentary.
An echocardiography substudy of the STEP-HFpEF Program found once-weekly semaglutide 2.4 mg attenuated adverse cardiac remodeling versus placebo over 52 weeks. PICO summary and expert commentary.
A pooled secondary analysis of the STEP-HFpEF and STEP-HFpEF DM trials examined whether baseline atrial fibrillation modified the benefit of once-weekly semaglutide 2.4 mg in obesity-related HFpEF. PICO summary and expert commentary.
An echocardiography substudy of the STEP-HFpEF Program found that once-weekly semaglutide 2.4 mg attenuated adverse cardiac remodeling versus placebo over 52 weeks. PICO summary and expert commentary.